The “American College of Radiology] Committee on Drugs and Contrast Media considers the risk of [‘nephrogenic’ systemic fibrosis] among patients exposed to standard or lower than standard doses of group II [gadolinium-based contrast agents] is ... possibly nonexistent...”
The American College of Radiology, based on more opinion than evidence, guided Group II agents—such as MultiHance—as having “sufficiently low or possibly nonexistent” risk for gadolinium-induced systemic fibrosis. acr.org/Clinical-Resou… #gadolinium ☠️ #radiology ☢️ #Nephrology
The result is that the adverse event for ‘nephrogenic’ systemic fibrosis is now the number one ranked adverse event with the American College of Radiology Group II agent, MultiHance per the FDA Adverse Events Reporting System. #gadolinium ☠️ #patientsafety#radiology ☢️
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Now: “Dialyzing the Undocumented: Driving Policy with Data”
by Dr. Lilia Cervantes, M.D.
Denver Health Medical Center and the University of Colorado Anschutz Medical Group @Cervantes_Lily1 University of New Mexico Health Science Center Department of Medicine Grand Rounds
“Patients sometimes consumed foods [knowingly] high in potassium,” in order to gain admission — @Cervantes_Lily1 University of New Mexico Health Science Center Department of Medicine Grand Rounds
“So, you are asking me to keep a patient sicker so you can make more money? I am sorry, that is not why I became a physician,” @Cervantes_Lily1 University of New Mexico Health Science Center Department of Medicine Grand Rounds
“Around 2012 or 2013, researchers identified evidence that gadolinium retention was connected to illness in patients with normal kidney function.” scholar.google.com/scholar_case?c…
“In September 2017, after the FDA voted to add concerns about gadolinium retention on warning labels, [gadolinium-based contrast agent] manufacturers, including Defendants, issued a new joint warning to patients with normal kidney function.” scholar.google.com/scholar_case?c…
“The warning [RE: #gadolinium retention] also directed physicians to advise patients of these concerns.”
“Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors,“ is now in press—sciencedirect.com/science/articl…
“[I]t is known that during those at least 6 weeks [after exposure to gadolinium-based contrast agent] equilibrium has not been reached and [gadolinium] can be measured for all [gadolinium-based contrast agents] in tissue,” fda.gov/downloads/Advi…
“It is important to note that the exact mechanism and in particular other co-factors that are likely needed to trigger [‘nephrogenic’ systemic fibrosis] are still unknown,” fda.gov/downloads/Advi…
“[T]he levels of gadolinium in the body considered normal in the absence of any [gadolinium-based contrast agent] exposure is, for practical purposes, zero,” fda.gov/downloads/Advi…